Full Text View
Tabular View
No Study Results Posted
Related Studies
Concomitant Chemo-Radiotherapy in Locally Advanced Non Small Cell Lung Cancer
This study has been terminated.
First Received: September 12, 2005   Last Updated: October 31, 2007   History of Changes
Sponsors and Collaborators: Institut Bergonié
Sanofi-Aventis
Information provided by: Institut Bergonié
ClinicalTrials.gov Identifier: NCT00210171
  Purpose

Feasibility of pragmatic concomitant chemo-radiotherapy association with 1 cycle of Induction chemotherapy, weekly chemo-radiotherapy, and consolidation chemotherapy.


Condition Intervention Phase
Carcinoma, Non-Small-Cell Lung
Procedure: Toxicity : Time to progression, 1 and 2 years survival
Phase II

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: Multicentric Phase II Study of Concomitant Chemo-Radiotherapy in Locally Advanced Non Small Cell Lung Cancer, With :- Induction Chemotherapy by Cisplatin - Docetaxel- Concomitant Chemo-Radiotherapy by Weekly Cisplatin - Docetaxel- Consolidation Chemotherapy by Docetaxel

Resource links provided by NLM:


Further study details as provided by Institut Bergonié:

Primary Outcome Measures:
  • Objective response

Secondary Outcome Measures:
  • Toxicity
  • Time to progression
  • 1 and 2 years survival

Estimated Enrollment: 43
Study Start Date: May 2004
Study Completion Date: March 2007
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

Histologically or cytologically confirmed newly diagnosed, untreated, unresectable stage IIIA or stage IIIB non-small cell lung cancer Not scheduled for curative cancer surgery No pleural effusion At least 1 bidimensionally or unidimensionally measurable lesion Age 18 years et 70 years; Performance Status < 2 Loss of weight < 10 % in past 6 months life expectancy 12 weeks; Bilirubin normal ASAT (SGOT) et ALAT (SGPT) 1,5 times upper limit of normal; Alcalin phosphatases 5 times upper limit of normal; Créatinin 1,5 x times upper limit of normal; Absolute neutrophil count greater than 2.109/l; Platelet count greater than 100.109/l; Hémoglobin ³ 10 g/ dl; Respiratory function : FEV1>50% write Consent

Exclusion criteria:

Pregnant or nursing; Fertile patients who don't used effective contraception; No other malignancy within past 5 years except inactive carcinoma in situ of the cervix or nonmelanoma skin cancer ; Neuropathy grade NCI-CTC 2; Past thoracic radiotherapy; Past chemotherapy, immunotherapy or biologic therapy for non small cell lung cancer ; Respiratory deficiency FEV1 < 45% ; Hypersensibility to docetaxel or cisplatin; At least 4 weeks since other concurrent investigational agents;

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00210171

Locations
France
Institut Bergonié - Centre Régional de Luttre Contre le Cancer de Bordeaux et du Sud Ouest
Bordeaux, France, 33076
Centre de radiothérapie d'Agen
Agen, France, 47000
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, France, 33076
Hôpital Robert Boulin
Libourne, France, 33500
Clinique Francheville
Perigueux, France, 24000
Clinique Tivoli
Bordeaux, France, 33000
Polyclinique Bordeaux Nord
Bordeaux, France, 33000
Sponsors and Collaborators
Institut Bergonié
Sanofi-Aventis
Investigators
Principal Investigator: François CHOMY, MD Institut Bergonié
  More Information

No publications provided

Study ID Numbers: IB2004-20, BIB-01
Study First Received: September 12, 2005
Last Updated: October 31, 2007
ClinicalTrials.gov Identifier: NCT00210171     History of Changes
Health Authority: France: Afssaps - French Health Products Safety Agency

Keywords provided by Institut Bergonié:
Carcinoma
Stage IIIA Non Small Cell Lung
Stage IIIB Non-Small-Cell Lung
Concomitant chemo-radiotherapy
Consolidation chemotherapy

Study placed in the following topic categories:
Docetaxel
Thoracic Neoplasms
Cisplatin
Respiratory Tract Diseases
Lung Neoplasms
Lung Diseases
Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Carcinoma

Additional relevant MeSH terms:
Thoracic Neoplasms
Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site
Neoplasms by Histologic Type
Respiratory Tract Diseases
Lung Neoplasms
Lung Diseases
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Carcinoma

ClinicalTrials.gov processed this record on September 02, 2009